Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging

被引：0
作者：
Giovanni Paganelli
Maddalena Sansovini
Emanuela Scarpi
机构：
[1] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS,Nuclear Medicine Unit
[2] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS,Unit of Biostatistics and Clinical Trials
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Capecitabine; Neuroendocrine Tumor; Peptide Receptor Radionuclide Therapy; Uptake Score; Combine Therapy Group;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1777 / 1778
页数：1
相关论文
共 18 条
[1]  
Sansovini M(2017)Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE Eur J Nucl Med Mol Imaging 44 490-9
[2]  
Severi S(2015)SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors Mol Imaging Biol 17 313-8
[3]  
Ianniello A(2017)Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors N Engl J Med 376 125-35
[4]  
Nicolini S(undefined)undefined undefined undefined undefined-undefined
[5]  
Fantini L(undefined)undefined undefined undefined undefined-undefined
[6]  
Mezzenga E(undefined)undefined undefined undefined undefined-undefined
[7]  
Kratochwil C(undefined)undefined undefined undefined undefined-undefined
[8]  
Stefanova M(undefined)undefined undefined undefined undefined-undefined
[9]  
Mavriopoulou E(undefined)undefined undefined undefined undefined-undefined
[10]  
Holland-Letz T(undefined)undefined undefined undefined undefined-undefined
12